These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 30180806)

  • 21. [The efficacy and safety of tolvaptan on treating heart failure patients with hyponatremia].
    Li L; Bai H; Zhu WL;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):936-40. PubMed ID: 22321279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential Effectiveness of Tolvaptan to Improve Ascites Unresponsive to Standard Diuretics and Overall Survival in Patients with Decompensated Liver Cirrhosis.
    Yamada T; Ohki T; Hayata Y; Karasawa Y; Kawamura S; Ito D; Kojima K; Seki M; Toda N; Tagawa K
    Clin Drug Investig; 2016 Oct; 36(10):829-35. PubMed ID: 27405984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Utility of Tolvaptan in the Perioperative Management of Severe Hyponatremia During Liver Transplantation: A Case Report.
    Parekh A; Rajaram P; Patel G; Subramanian RM
    Transplant Proc; 2017 Dec; 49(10):2399-2401. PubMed ID: 29198689
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of tolvaptan in cirrhotic patients: a systematic review and meta-analysis of randomized controlled trials.
    Chai L; Li Z; Wang T; Wang R; Pinyopornpanish K; Cheng G; Qi X
    Expert Rev Gastroenterol Hepatol; 2023; 17(10):1041-1051. PubMed ID: 37794713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial.
    Ginès P; Wong F; Watson H; Milutinovic S; del Arbol LR; Olteanu D;
    Hepatology; 2008 Jul; 48(1):204-13. PubMed ID: 18508290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Oral Tolvaptan Therapy in Hospitalized Cirrhotic Patients with Hyponatremia.
    Garg R; Kaur K; Aggarwal S; Singh N
    J Assoc Physicians India; 2018 Dec; 66(12):49-52. PubMed ID: 31315326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
    Morris JH; Bohm NM; Nemecek BD; Crawford R; Kelley D; Bhasin B; Nietert PJ; Velez JCQ
    Am J Kidney Dis; 2018 Jun; 71(6):772-782. PubMed ID: 29478867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum Copeptin and Zinc-α2-glycoprotein Levels Are Novel Biomarkers of Tolvaptan Treatment in Decompensated Cirrhotic Patients with Ascites.
    Shigefuku R; Iwasa M; Eguchi A; Tempaku M; Tamai Y; Suzuki T; Takei Y
    Intern Med; 2021; 60(21):3359-3368. PubMed ID: 34719623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of tolvaptan on acute heart failure with hyponatremia--a randomized, double blind, controlled clinical trial.
    Shanmugam E; Doss CR; George M; Jena A; Rajaram M; Ramaraj B; Anjaneyan K; Kanagesh B
    Indian Heart J; 2016 Apr; 68 Suppl 1(Suppl 1):S15-21. PubMed ID: 27056648
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia.
    Dahl E; Gluud LL; Kimer N; Krag A
    Aliment Pharmacol Ther; 2012 Oct; 36(7):619-26. PubMed ID: 22908905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of Tolvaptan Addition to Furosemide in Normo- and Hyponatremia Patients with Heart Failure and Chronic Kidney Disease Stages G3b-5: A Subanalysis of the K-STAR Study.
    Tominaga N; Kida K; Inomata T; Sato N; Izumi T; Akashi YJ; Shibagaki Y
    Am J Nephrol; 2017; 46(5):417-426. PubMed ID: 29130954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: A randomized study.
    Uojima H; Hidaka H; Nakayama T; Sung JH; Ichita C; Tokoro S; Masuda S; Sasaki A; Koizumi K; Egashira H; Kako M
    World J Gastroenterol; 2017 Dec; 23(45):8062-8072. PubMed ID: 29259382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and Efficacy of Tolvaptan in Korean Patients with Hyponatremia Caused by the Syndrome of Inappropriate Antidiuretic Hormone.
    Han SW; Yi JH; Kang KP; Kim HY; Kim SW; Choi HY; Ha SK; Kim GH; Kim YW; Jeong KH; Shin SK; Kim HJ
    J Korean Med Sci; 2018 Apr; 33(15):e112. PubMed ID: 29629516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan.
    Sakaida I; Nakajima K; Okita K; Hori M; Izumi T; Sakurai M; Shibasaki Y; Tachikawa S; Tsubouchi H; Oka H; Kobayashi H
    J Gastroenterol; 2015 Oct; 50(10):1047-53. PubMed ID: 25689936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Positive Response to Tolvaptan Treatment Would Be a Good Prognostic Factor for Cirrhotic Patients with Ascites.
    Kida Y
    Dig Dis; 2019; 37(3):239-246. PubMed ID: 30625470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure.
    Cyr PL; Slawsky KA; Olchanski N; Krasa HB; Goss TF; Zimmer C; Hauptman PJ
    Am J Health Syst Pharm; 2011 Feb; 68(4):328-33. PubMed ID: 21289328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Current options of treatment of hyponatremia].
    Tesař V
    Vnitr Lek; 2016; 62 Suppl 6():97-101. PubMed ID: 28124939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term low-dose tolvaptan treatment in hospitalized male patients aged >90 years with hyponatremia: Report on safety and effectiveness.
    Liu YH; Han XB; Fei YH; Xu HT
    Medicine (Baltimore); 2017 Dec; 96(52):e9539. PubMed ID: 29384972
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis.
    Okita K; Sakaida I; Okada M; Kaneko A; Chayama K; Kato M; Sata M; Yoshihara H; Ono N; Murawaki Y
    J Gastroenterol; 2010 Sep; 45(9):979-87. PubMed ID: 20387081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolvaptan in hospitalized cancer patients with hyponatremia: a double-blind, randomized, placebo-controlled clinical trial on efficacy and safety.
    Salahudeen AK; Ali N; George M; Lahoti A; Palla S
    Cancer; 2014 Mar; 120(5):744-51. PubMed ID: 24895288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.